**2.8 Treatment of SARS-CoV2 infection for children receiving bone marrow transplantation and current recommendations**

Of 318 HSCT receipts with COVID-19 infection, 184 with allogeneic HSCT, 134 with autologous HSCT were included in one study. In the allogeneic HSCT group, fifteen cases were ≤ ten years old; eleven were between 11 and 20 years old. Three patients were ≤ ten years old; none were 11-20 years old in the other group. Therefore, AML, ALL, MDS are the leading diagnoses for allogeneic HSCT. Fiftyfive patients had a severe presentation of COVID-19 infection requiring mechanical ventilation. In the allogeneic HSCT group, 42% had a myeloablative regimen, 56% took a reduced-intensity conditioning regimen (RIC), 45% received TBI (total body irradiation) based conditioning regimen. In moderate–severe cases, COVID-19 convalescent plasma remdesivir, tocilizumab, Hydroxychloroquine, azithromycin were commonly used. In addition, Lopinavir, ritonavir, methylprednisolone, oseltamivir, ribavirin, acyclovir, famciclovir, antibacterial agents were also used. After 30 days of transplantation, overall survival was 68% for the allogeneic HSCT group, 67% for autologous HSCT receipts. Male sex, age older than 50, and COVID-19 within 12 months of transplantation was strongly associated with mortality [45].

The COVID-19 Treatment Guidelines include the following recommendations for HSCT and cellular therapy receipts and donors;

